Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | May 18, 2011 | May 19, 2011 |
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director · 10% owner | June 11, 2026 | June 16, 2026 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director · Co-Chief Executive Officer · 10% owner | June 12, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date May 18, 2011 · Filed May 19, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2011-05-18 transaction · row 1
1 source rowRow 1 · 2011-05-18 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.09 · Expires 2015-05-20 | Direct | 0 |
Reported balance
After 2011-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-05-18 · Exercise / conversion · Disposed 1,000 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
PULSE BIOSCIENCES, INC.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.89 · Expires 2036-06-11 | Direct | 12,495 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 12,495 · Balance 12,495 F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
F2: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026.
Summit Therapeutics Inc.
Report date June 12, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 573,883,879 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Purchase · Acquired 3,810,000 · Balance 573,883,879 |
| Common StockSEC Table I · non-derivative | IndirectBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee | 25,824,474 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 25,824,474 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectImmediate family member of Spouse | 76,680 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,680 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 31,000 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,000 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee | 10,199,776 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 10,199,776 F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Achaogen, Inc.
Report date March 18, 2019 · Filed March 20, 2019
Section 16 reporting ended · disclosed 2019-03-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 5,555,414 |
Ending reported balance
After 2019-03-20 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-03-18 · Sale · Disposed 271,879 · Balance 6,561,423 Row 2 · 2019-03-19 · Sale · Disposed 956,009 · Balance 5,605,414 Row 3 · 2019-03-20 · Sale · Disposed 50,000 · Balance 5,555,414 |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 30,000 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 30,000 F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 100,255 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100,255 F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnote | 72,170 |
Reported balance
Holding disclosure · report date 2019-03-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 72,170 F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Blaze-On Corporation, of which the Reporting Person is the sole officer and director.
F2: Shares held by Robert W. Duggan Foundation, of which the Reporting Person is the President.
F3: Shares are held by Genius Inc., of which the Reporting Person is the sole shareholder.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 12, 2026 16:28 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 3,810,000 | $13.12 | $49,987,200.00 |
DisclosureSEC source: 0001055919-26-000007 · wk-form4_1781281727.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,883,879 Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 12,495 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020717 · rdgdoc.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,495 Underlying: Common Stock · 12,495 shares Expires 2036-06-11 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2026. Read SEC document |
| June 11, 2026 Filed Jun 16, 2026 01:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001437749-26-020717 · rdgdoc.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 22:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 100,000 | $14.60 | $1,460,000.00 |
DisclosureSEC source: 0001055919-26-000005 · wk-form4_1780610903.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee Disclosed balance after: 25,824,474 F1 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 11, 2026 Filed May 11, 2026 22:52 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 660,233 | $19.69 | $12,999,987.77 |
DisclosureSEC source: 0001437749-26-016188 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,211,433 F1 · kind: The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · price: The shares reported herein were acquired through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale. Read SEC document |
| May 11, 2026 Filed May 15, 2026 23:25 UTC Amendment | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 660,233 | $19.69 | $12,999,987.77 |
DisclosureSEC source: 0001437749-26-017478 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,370,047 F1 · kind: The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. F2 · price: The shares reported herein were acquired through the Company's at-the-market equity offering program at the prevailing market bid price or better at the time of sale. F3 · balance_after: Includes approximately 700 shares inadvertently not reported in the Company's Schedule 14A filed on May 11, 2026. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:50 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 11,232 | $8.76 Strike: $17.52 | $98,392.32 |
DisclosureSEC source: 0001055919-26-000003 · wk-form4_1767747017.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,232 Underlying: Common Stock · 11,232 shares Expires 2036-01-02 F2 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 26,680 | $18.74 | $499,983.20 |
DisclosureSEC source: 0001055919-25-000003 · wk-form4_1761250107.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Immediate family member of Spouse Disclosed balance after: 76,680 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 266,808 | $18.74 | $4,999,981.92 |
DisclosureSEC source: 0001055919-25-000003 · wk-form4_1761250107.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee Disclosed balance after: 25,724,474 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. F2 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 23, 2025 20:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 13,980,789 | $18.74 | $261,999,985.86 |
DisclosureSEC source: 0001055919-25-000003 · wk-form4_1761250107.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,073,879 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of October 21, 2025, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person and certain other parties at a purchase price of $18.74 per share. The transaction is anticipated to close on or about October 23, 2025. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 23:32 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 5,000 | $18.07 | $90,350.00 |
DisclosureSEC source: 0001599298-25-000142 · wk-form4_1757633519.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,093,090 Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:32 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | PurchaseCommon Stock | 333,394 | $17.68 | $5,894,405.92 |
DisclosureSEC source: 0001599298-25-000142 · wk-form4_1757633519.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 556,088,090 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2025 Filed Sep 13, 2025 00:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 34,659 | $14.66 | $508,100.94 |
DisclosureSEC source: 0001437749-25-028988 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,551,200 F1 · price: Volume-weighted average price. The price per share actually paid by the Reporting Person ranged from $14.51 to $14.81 per share. For all transactions reported in this Form 4 using a weighted average price, the Reporting Person undertakes upon request by the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,792 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027394 · rdgdoc.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,792 Underlying: Common Stock · 20,792 shares Expires 2035-08-15 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2025. Read SEC document |
| August 15, 2025 Filed Aug 20, 2025 01:17 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001437749-25-027394 · rdgdoc.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-15 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:55 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionStock Option (right to buy) · Derivative | 74,545 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001599298-25-000106 · wk-form4_1748897749.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,545 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 30, 2025, the Reporting Person exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person did not sell the underlying shares. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option vested in four equal quarterly installments on March 31, June 30, September 30 and December 31, 2024. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:55 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | Exercise / conversionCommon Stock | 74,545 | $2.64 | $196,798.80 |
DisclosureSEC source: 0001599298-25-000106 · wk-form4_1748897749.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,754,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 30, 2025, the Reporting Person exercised an option to purchase 74,545 shares of the Issuer's common stock at an exercise price of $2.64 per share. The Reporting Person did not sell the underlying shares. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:09 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 9,590,558 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001599298-25-000093 · wk-form4_1746137388.xml · derivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 9,590,558 Underlying: Common Stock · 9,590,558 shares Expires 2033-10-13 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:09 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 400,000 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001599298-25-000093 · wk-form4_1746137388.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-09-09 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 29, 2025 Filed May 1, 2025 22:09 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 1,040,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001599298-25-000093 · wk-form4_1746137388.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,040,000 Underlying: Common Stock · 1,040,000 shares Expires 2032-06-28 F2 · price: Not applicable. F1 · derivative.exercise_date: Effective April 29, 2025, these stock options were amended from performance-based stock options to time-based stock options. The shares underlying the option vest as follows: (i) 50% of such shares vested as of April 29, 2025, and (ii) the remaining 50% of such shares vest in three equal annual installments, with the first such installment occurring on October 13, 2025. F3 · balance_after: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 21:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherWarrant (right to buy) · Derivative | 3,985,055 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001599298-25-000058 · wk-form4_1744233117.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,985,055 shares Expires 2029-12-24 F1 · kind: On April 8, 2025, the Reporting Person exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share. Read SEC document |
| April 08, 2025 Filed Apr 9, 2025 21:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | OtherCommon Stock | 3,985,055 | $1.58 | $6,296,386.90 |
DisclosureSEC source: 0001599298-25-000058 · wk-form4_1744233117.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,680,151 F1 · kind: On April 8, 2025, the Reporting Person exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:49 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 10,724 | $9.18 Strike: $18.35 | $98,446.32 |
DisclosureSEC source: 0001599298-25-000030 · wk-form4_1736210941.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,724 Underlying: Common Stock · 10,724 shares Expires 2035-01-02 F4 · price: The option was issued to the reporting person pursuant to the Director Retainer Option Election Plan of issuer in lieu of retainer fees of $98,400. F3 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 24,656 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 0 Underlying: Common Stock · 24,656 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F3 · ownership.nature: Shares and Warrants held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 24,656 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 0 Underlying: Common Stock · 24,656 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F3 · ownership.nature: Shares and Warrants held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 34,510 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 0 Underlying: Common Stock · 34,510 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F2 · ownership.nature: Shares and Warrants held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 34,510 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 0 Underlying: Common Stock · 34,510 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F2 · ownership.nature: Shares and Warrants held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 2,593,912 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,593,912 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherWarrants (right to buy) · Derivative | 2,593,912 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,593,912 shares Expires 2029-07-03 F4 · price: The Reporting Person acquired the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F5 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 49,312 | $11.00 | $542,432.00 |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 450,189 F1 · kind: On December 18, 2024, the Reporting Person exercised warrants to purchase shares of the Issuer's common stock, at an exercise price of $11.00 per share. F3 · ownership.nature: Shares and Warrants held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 69,020 | $11.00 | $759,220.00 |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 630,109 F1 · kind: On December 18, 2024, the Reporting Person exercised warrants to purchase shares of the Issuer's common stock, at an exercise price of $11.00 per share. F2 · ownership.nature: Shares and Warrants held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| December 18, 2024 Filed Dec 19, 2024 02:36 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 5,187,824 | $11.00 | $57,066,064.00 |
DisclosureSEC source: 0000950170-24-138177 · ownership.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,516,541 F1 · kind: On December 18, 2024, the Reporting Person exercised warrants to purchase shares of the Issuer's common stock, at an exercise price of $11.00 per share. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:02 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 55,256 | $17.18 | $949,298.08 |
DisclosureSEC source: 0001437749-24-037766 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,328,717 F1 · price: Volume-weighted average price. Read SEC document |
| December 12, 2024 Filed Dec 17, 2024 11:05 UTC | PULSE BIOSCIENCES, INC. PLES · Entity 1151 | PurchaseCommon Stock | 45,404 | $17.13 | $777,770.52 |
DisclosureSEC source: 0000950170-24-136901 · ownership.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,273,461 F1 · price: Volume-weighted average price. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:30 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 50,000 | $17.42 | $871,000.00 |
DisclosureSEC source: 0001437749-24-037509 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,228,057 Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:30 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 6,054 | $16.74 | $101,343.96 |
DisclosureSEC source: 0001437749-24-037509 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,178,057 F1 · price: Volume-weighted average price. Read SEC document |
| September 12, 2024 Filed Sep 13, 2025 00:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 145,140 | $14.41 | $2,091,467.40 |
DisclosureSEC source: 0001437749-25-028988 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,709,140 F3 · price: Volume-weighted average price. The price per share actually paid by the Reporting Person ranged from $13.90 to $14.75 per share. Read SEC document |
| September 11, 2024 Filed Sep 13, 2024 22:25 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantCommon Stock | 3,325,991 | $22.70 | $75,499,995.70 |
DisclosureSEC source: 0001599298-24-000139 · wk-form4_1726266298.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · Co-Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 551,695,096 F1 · shares: Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Reporting Person at a purchase price of $22.70 per share. The transaction closed on September 13, 2024. F2 · balance_after: Excludes shares underlying options and warrants held by the Reporting Person. Read SEC document |
| September 11, 2024 Filed Sep 13, 2025 00:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseCommon Stock | 12,800 | $14.77 | $189,056.00 |
DisclosureSEC source: 0001437749-25-028988 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,564,000 F2 · price: Volume-weighted average price. The price per share actually paid by the Reporting Person ranged from $14.57 to $14.79 per share. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 24,656 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 9 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 24,656 Underlying: Common Stock · 24,656 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F4 · ownership.nature: Shares and warrants are held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 24,656 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 8 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 24,656 Underlying: Common Stock · 24,656 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F4 · ownership.nature: Shares and warrants are held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 34,510 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 7 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 34,510 Underlying: Common Stock · 34,510 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F3 · ownership.nature: Shares and warrants are held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 34,510 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 6 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 34,510 Underlying: Common Stock · 34,510 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F3 · ownership.nature: Shares and warrants are held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 2,593,912 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 5 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,593,912 Underlying: Common Stock · 2,593,912 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | PurchaseWarrant (right to buy) · Derivative | 2,593,912 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · derivative · entry 4 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,593,912 Underlying: Common Stock · 2,593,912 shares Expires 2029-07-03 F2 · derivative.exercise_price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F1 · price: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 49,312 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · nonDerivative · entry 3 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 2 Disclosed balance after: 400,877 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F4 · ownership.nature: Shares and warrants are held by Blazon Corporation, of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 69,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · nonDerivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Affiliated Company 1 Disclosed balance after: 561,089 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. F3 · ownership.nature: Shares and warrants are held by Genius 24C Inc., of which the Reporting Person is the sole shareholder. Read SEC document |
| July 03, 2024 Filed Jul 9, 2024 13:16 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | OtherCommon Stock | 5,187,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-022358 · rdgdoc.xml · nonDerivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,172,003 F1 · kind: The Reporting Person acquired the shares of common stock and the warrants pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering (the "Rights Offering"), as disclosed in the Registration Statement on Form S-3, as amended, and certain Current Reports on Form 8-K filed by the Issuer with the SEC. F2 · price: Pursuant to the terms of the Rights Offering, the Reporting Person purchased units at a price of $10.00 per unit, with each unit consisting of one share of common stock and two warrants each to purchase one half share of common stock at an exercise price of $11.00 per whole share. The warrants differ only in their redemption provisions. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:33 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 16,247 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021125 · rdgdoc.xml · derivative · entry 2 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,247 Underlying: Common Stock · 16,247 shares Expires 2034-06-06 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2024. Read SEC document |
| June 06, 2024 Filed Jun 24, 2024 23:33 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001437749-24-021125 · rdgdoc.xml · derivative · entry 1 DUGGAN ROBERT W · CIK 0001055919 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 6, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.